Darzalex Faspro
(DAR-zah-lex FAS-proh)
A combination of daratumumab and hyaluronidase used alone or with other drugs to treat adults with certain types of multiple myeloma or light chain amyloidosis. It is also being studied in the treatment of other types of cancer. Daratumumab binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Hyaluronidase allows daratumumab to be given by injection under the skin. Darzalex Faspro can be given in less time than daratumumab alone, which is given as an infusion. Also called daratumumab and hyaluronidase.